Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adenocarcinoma of the Rectum: early-phase trial registry
5 of 12 indexed Adenocarcinoma of the Rectum trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 5 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Adenocarcinoma of the Rectum: 12 US clinical trials tracked, 5 recruiting.
Adenocarcinoma of the Rectum is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition adenocarcinoma-of-the-rectum
OPEN 5 | RECR 42% | LATE 0 | EARLY 8 | RANK #1429 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Alzheimer Disease, Early Onset (42% recruiting · 12 trials)
Adenocarcinoma of the Rectum lists 5 open slots (42% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adenocarcinoma of the Rectum on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adenocarcinoma of the Rectum is recruiting below its size-band peers.
5 of 12 indexed trials (41.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adenocarcinoma of the Rectum research.
National Cancer Institute (NCI) accounts for 5 of 12 trials (41.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Adenocarcinoma of the Rectum trials plan to enrol fewer than 100 people.
Median target enrolment is 43 among the 12 trials that report a genuine target (sentinel values excluded). 10 of those (83.3%) plan for fewer than 100 participants.
-
Adenocarcinoma of the Rectum research is mostly interventional.
10 interventional and 2 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NRG Oncology
NCT05080673
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Memorial Sloan Kettering Cancer Center
NCT04668872
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
Case Comprehensive Cancer Center
NCT04624555
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT05672524
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT06637462
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
AbbVie (prior sponsor, Abbott)
NCT00707889
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
National Cancer Institute (NCI)
NCT00028496
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
NCT00397384
Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum
National Cancer Institute (NCI)
NCT00006094
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Washington University School of Medicine
NCT02641691
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
NCT00433576
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
NCT00023933
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Adenocarcinoma of the Rectum records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adenocarcinoma of the Rectum trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adenocarcinoma of the Rectum page
12 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Adenocarcinoma of the Rectum trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Adenocarcinoma of the Rectum trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma of the Rectum condition card totals 12 registered trials; most-linked intervention fluorouracil; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.